Key Takeaways AbbVie projects revenue growth in 2025 despite Humira sales falling by over 54% in the first half of 2025.Skyrizi and Rinvoq are fueling gains with new launches, head-to-head data and expanding indications.AbbVie is also expanding in oncology and neuroscience, adding new drugs and boosting migraine uptake.AbbVie (ABBV) expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship drug Humira over two years ago. The drug, which went off-patent i ...